一种ACOT4多核酸变体与诺福克岛和英国生物银行队列中的心血管风险有关
Jacob W I Meyjes-Brown1, Heidi G Sutherland1, Kim Ngan Tran1
1Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane City 4000, QLD, Australia.
Genes
|February 27, 2026
概括
ACOT4基因中的一种新型遗传变异与降低血压和提高胆固醇有关,可能会影响心血管疾病风险. 这一发现提供了对脂质代谢和心脏健康的遗传调节的见解.
科学领域:
- 遗传学 是一个遗传学.
- 心血管疾病研究研究
- 代谢综合征是代谢综合征的一种.
背景情况:
- 胆固醇和血压是具有遗传成分的关键心血管疾病 (CVD) 风险因素.
- 识别与心血管疾病特征相关的遗传变异对于了解疾病病因至关重要.
研究的目的:
- 识别与胆固醇水平和血压相关的新型遗传编码变体.
- 在独立的队列中验证这些协会.
主要方法:
- 利用诺福克岛健康研究 (NIHS) 进行初始变种发现.
- 利用英国生物库的整个外体组数据来验证暗示性关联.
- 分析了遗传变异与心血管疾病/代谢综合征特征之间的关联.
主要成果:
- 在ACOT4基因中发现了一种与脂质代谢相关的新型误解多核酸变异 (MNV).
- 在NIHS和英国生物银行队列中,MNV显示出与较低的升高血压和较高的总胆固醇存在一致的关联.
- 在的预测表明,MNV可能会破坏ACOT4蛋白的稳定,影响脂质代谢途径.
结论:
- 在ACOT4中编码的新型MNV对心血管健康有重大影响.
- 这种变异影响脂质代谢和血压调节.
- 进一步的研究可以探索脂质代谢的遗传调节及其在心血管疾病中的作用.
相关概念视频
Comparing Copy Number Variations and SNPs
11.6K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
11.6K
Single Nucleotide Polymorphisms-SNPs
14.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
